Within each of these indications, the availability of highly efficacious biologic therapies has vastly improved the clinical management of patients with active disease despite the use of conventional therapies; the set of biologic drugs approved in CD, Ps, and/or RA includes monoclonal antibodies (adalimumab, certolizumab, golimumab, infliximab, rituximab, tocilizumab, ustekinumab) and recombinant fusion proteins (abatacept, etanercept) [1] . However, these are premium-priced products relative to traditional oral medications [8] . The added expenses of biologic drugs highlight the ongoing need for comparative effectiveness studies to optimize decisions about their use. To date, head-to-head randomized clinical trials comparing alternative biologic regimens are limited to trials of etanercept versus ustekinumab in Ps [9] and abatacept versus infliximab in RA [10] . In the absence of direct [2] , is typically characterized by recurring exacerbations of abdominal pain, diarrhea, fever, and weight loss [3] .
Ps is a common, debilitating autoimmune disorder that primarily affects the skin and joints, with a prevalence rate of 2.1% among US adults [4] . Patients with Ps experience physical pain and diminished quality of life due to erythematous plaques on the body surface [5, 6] . RA, a chronic inflammatory disorder, is prevalent in approximately 1% of US adults and can result in progressive joint damage and impaired mobility [7] .
to reflect general differences in the time horizon and design of phase 3 biologic drug trials between the three disease areas. Trials of adalimumab and infliximab in CD were included if they followed patients for a minimum of 52 weeks, reported response and remission rates based on the Crohn's Disease Activity Index (CDAI), and featured an induction-only placebo arm (i.e., patients were switched to placebo after receiving an induction regimen of the biologic), which is the usual comparison arm protocol that has been used in phase 3 trials of biologic drugs in CD. Studies of adalimumab, etanercept, infliximab, or ustekinumab for Ps were selected if they followed patients for at least 10 weeks, 
MATERIALS AND METHODS

Study Inclusion Criteria
Statistical Analysis
MTC Meta-Analysis
For each indication, meta-analyses were conducted to synthesize efficacy results from the included trials and derive pooled response and remission rates for each biologic regimen. The evidence synthesis method in the York/Woolacott cost-effectiveness model of biologic drugs for psoriasis was adapted for this MTC study [32] .
Bayesian logistic regression was applied to
analyze the dichotomous outcomes using Markov chain Monte Carlo with Gibbs sampling method by indication. An MTC meta-analysis approach was selected for its ability to synthesize summarylevel clinical evidence from multiple studies while adjusting for between-trial differences in placebo response rates [33] [34] [35] ; in contrast to standard meta-analyses, this method also allowed for the combination of data from direct comparisons (i.e., trials comparing two different biologic drugs) with indirect evidence from placebo-controlled trials of biologics [36] . Using MTC, the relative efficacy of each biologic therapy was calculated in terms of incremental response/remission rate, defined as the difference in response/remission rates between the therapy and placebo. Based on the posterior distribution of the relative efficacy, the posterior mean was calculated as a point estimate of the relative efficacy, and 95% CIs were approximated using the highest posterior density method. All Bayesian analyses were conducted using R/OpenBUGS software (R Foundation for Statistical Computing).
Number Needed to Treat
The number needed to treat (NNT) per additional responder/remitter associated with each biologic drug by indication was estimated using the point estimate of relative efficacy. NNT can be interpreted as the number of patients who need to be treated with a particular drug in order to achieve one additional positive outcome (i.e., response, remission) [37] . 
Meta-Analysis Results in Ps
In the MTC meta-analysis of biologic trials in Ps, incremental PASI 75 response rates relative to placebo were highest for infliximab (74.9%) and ustekinumab 90 mg (67.9%) ( Table 4 (Table 1) . Per-infusion drug cost for abatacept, infliximab, and tocilizumab were calculated based on an average weight of 70 kg in CD [11] and RA [26] , and 90 kg in Ps [14] . Administration cost per infusion was Drug acquisition and administration costs were prorated in order to obtain total costs over the specified time horizon within each indication.
RESULTS
Meta-Analysis Results in CD
In response rate (i.e., the difference in response rates between treatment vs. induction-only placebo) was 24.7% (95% CI 12.6%, 37.5%) for adalimumab and 20.8% (95% CI 7.7%, 34.9%) for infliximab ( Table 2) .
Adalimumab (23.6%; 95% CI 10.4%, 38.1%) also had a higher incremental remission rate compared to infliximab (14.9%; 95% CI 2.6%, 27.2%) ( Table 2) . 
Cross-Indication Results
In (Table 9) .
DISCUSSION
This study used MTC meta-analyses of published clinical trials to evaluate the cost per responder For both adalimumab and infliximab, response and remission rates are estimated among initial CR-70 responders only. Initial response status was assessed at week 4 for adalimumab and at week 2 for infliximab; the proportion of patients who achieved initial response was 58% for both therapies [11, 12] NNT is the number of patients who need to be treated in order to achieve one additional positive outcome (e.g., response, remission), and is defined as the inverse of absolute risk reduction. In the present analysis, patients with Crohn's disease without an initial response to adalimumab or infliximab were assumed to discontinue therapy at week 4, and achieve neither response nor remission at 1 year b Cost per additional responder/remitter was calculated as NNT per additional responder/remitter multiplied by the expected 1-year drug cost per patient. Drug cost per patient was estimated with the assumption that initial responders had 100% compliance to the indicated dosages up to week 52, while initial nonresponders only received the indicated dosages prior to week 4 NNT is the number of patients who need to be treated in order to achieve one additional positive outcome (e.g., response, remission), and is defined as the inverse of absolute risk reduction. In the present analysis, NNT per responder was calculated as 1/(probability of 12-week response with biologic -probability of 12-week response with placebo). NNT per remitter was similarly calculated b Cost per additional responder/remitter was calculated as NNT per additional responder/remitter multiplied by the expected 12-week drug cost per patient. Drug cost per patient was estimated with the assumption that patients had 100% compliance to the indicated dosages up to week 12 Table 6 Mixed treatment comparison meta-analysis of response and remission rates in rheumatoid arthritis NNT is the number of patients who need to be treated in order to achieve one additional positive outcome (e.g., response, remission), and is defined as the inverse of absolute risk reduction. In the present analysis, NNT per responder was calculated as 1/(probability of 6-month response with biologic -probability of 6-month response with placebo). NNT per remitter was similarly calculated b Cost per additional responder/remitter was calculated as NNT per additional responder/remitter multiplied by the expected 24-week drug cost per patient. Drug cost per patient was estimated with the assumption that patients had 100% compliance to the indicated dosages up to week 24 Table 8 Cross-indication costs per responder and remitter in psoriasis and rheumatoid arthritis Because CD, Ps, and RA are chronic disorders, the cost-effectiveness of biologic therapies for these indications should ideally be assessed over long 
